MedTrace Logo

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT01005888 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-06-11

Study results available
· View outcomes & findings →

Summary

The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.

Conditions

Interventions

BIOLOGICAL

C1 esterase inhibitor [human] (C1INH-nf)

DRUG

Placebo (saline)

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-14
Primary Completion
2007-08-22
Completion
2007-08-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01005888 on ClinicalTrials.gov